 |
|
|
| |
Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients
|
| |
| |
EASL: Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects - (06/30/22)
EASL: Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB) - (06/30/22)
EASL: Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729 - (06/30/22)
EASL 2022 June 22-26 London
EP Thi, AG Cole, G Heffernan, CL Iott, S Ozturk, SC Ganchua, D Nguyen, I Graves, V Ahuja, K Stever, K Fan, JG Quintero, SG Kultgen, M Shubina, B Liu, S Tang, TO Harasym, AM Lam and MJ Sofia Arbutus Biopharma Inc., Warminster PA, USA
|
| |
|
|
|
|
|
